Gayl Reader, MD
Cardiovascular Disease · Greenville, KYNPI 1467401729
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,201 of the $26,944 with a category attached, or 67.6%. Amgen accounts for 73.8% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2019 at $10,335 and has fallen 90.5% since, to $978 in 2025. Among cardiovascular disease clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 565 payments — averaging $47.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$20K
- Novartis$2K
- Johnson & Johnson$958
- Merck$800
- Boehringer Ingelheim$712
- AstraZeneca$507
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$18,20168%
- Travel & lodging$590%
- Food & beverage$8,68432%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 106 | $19,884 |
| Novartis | 146 | $1,926 |
| Johnson & Johnson | 71 | $958 |
| Merck | 45 | $800 |
| Boehringer Ingelheim | 45 | $712 |
| AstraZeneca | 23 | $507 |
| Pfizer | 28 | $473 |
| E.r. Squibb & Sons, L.L.C. | 21 | $313 |
| Amarin Pharma, Inc. | 20 | $228 |
| Esperion Therapeutics, Inc. | 11 | $191 |
| Sanofi-aventis U.S. LLC | 9 | $148 |
| Lexicon Pharmaceuticals, Inc. | 6 | $121 |
| Bayer | 6 | $117 |
| Scpharmaceuticals Inc. | 3 | $98 |
| Abiomed | 4 | $90 |
| Medtronic | 1 | $53 |
| Novo Nordisk | 3 | $45 |
| Boston Scientific | 2 | $42 |
| Amryt Pharma Holdings Ltd | 2 | $39 |
| Lundbeck LLC | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $30 |
| Terumo Medical Corporation | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Abbott | 1 | $16 |
| Chiesi USA, Inc. | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Aegerion Pharmaceuticals, Inc. | 1 | $12 |
| Biosense Webster, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,944 in reported general payments places this provider in the 90th percentile of 258 cardiovascular disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 651 | $510,232 |
| EntrestoSacubitril/Valsartan | 450 | $404,432 |
| XareltoRivaroxaban | 225 | $174,594 |
| JardianceEmpagliflozin | 169 | $141,646 |
| FarxigaDapagliflozin Propanediol | 138 | $116,028 |
| Repatha SureclickEvolocumab | 148 | $85,574 |
| BrilintaTicagrelor | 115 | $75,164 |
| VerquvoVericiguat | 83 | $72,018 |
| MultaqDronedarone Hcl | 59 | $62,674 |
| Repatha PushtronexEvolocumab | 71 | $49,532 |
| Praluent PenAlirocumab | 49 | $29,571 |
| NexletolBempedoic Acid | 47 | $20,588 |
| Metoprolol Succinate | 1,242 | $14,237 |
| DapagliflozinDapagliflozin Propanediol | 28 | $13,894 |
| VascepaIcosapent Ethyl | 30 | $13,877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $473 | $510,232651 claims |
| NovartisEntresto | $1,926 | $404,432450 claims |
| AstraZenecaFarxiga, Brilinta | $507 | $191,192253 claims |
| Johnson & JohnsonXarelto | $958 | $174,594225 claims |
| Boehringer IngelheimJardiance | $712 | $141,646169 claims |
| MerckVerquvo | $800 | $72,01883 claims |
| Sanofi-aventis U.S. LLCMultaq | $148 | $62,67459 claims |
| Esperion Therapeutics, Inc.Nexletol | $191 | $20,58847 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 258 cardiovascular disease providers in Kentucky.
Other cardiovascular disease in Greenville
- Amir PirachaLouisville$530K
- Dinesh KalraLouisville$316K
- William SkinnerLexington$312K
- Prabodh MehtaElizabethtown$133K
- John HarrisLouisville$129K
- David MoliternoLexington$115K
- Rohan SamsonLouisville$94K
- Srinivasa AppakonduHazard$91K
- Muhammad AkbarBowling Green$84K
- Jeffrey ReichardFlorence$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.